Business Description
Arovella Therapeutics Ltd
ISIN : AU0000182784
Description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.85 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 44.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 11.5 | |||||
| 3-Year EPS without NRI Growth Rate | 6.5 | |||||
| 3-Year FCF Growth Rate | 16.4 | |||||
| 3-Year Book Growth Rate | -16.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.74 | |||||
| 9-Day RSI | 45.95 | |||||
| 14-Day RSI | 48.39 | |||||
| 6-1 Month Momentum % | 55.22 | |||||
| 12-1 Month Momentum % | 105.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.44 | |||||
| Quick Ratio | 6.44 | |||||
| Cash Ratio | 6.23 | |||||
| Days Sales Outstanding | 939.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.8 | |||||
| Shareholder Yield % | -7.66 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -60061.11 | |||||
| Net Margin % | -48588.89 | |||||
| FCF Margin % | -36133.33 | |||||
| ROE % | -144.63 | |||||
| ROA % | -108.94 | |||||
| ROIC % | -2671.58 | |||||
| ROC (Joel Greenblatt) % | -7894.88 | |||||
| ROCE % | -144.2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 16.36 | |||||
| Price-to-Tangible-Book | 10.4 | |||||
| EV-to-EBIT | -21.43 | |||||
| EV-to-Forward-EBIT | -9.51 | |||||
| EV-to-EBITDA | -21.53 | |||||
| EV-to-Forward-EBITDA | -8.66 | |||||
| EV-to-Revenue | 10400.83 | |||||
| EV-to-Forward-Revenue | 4.99 | |||||
| EV-to-FCF | -26.58 | |||||
| Price-to-Net-Current-Asset-Value | 10.4 | |||||
| Price-to-Net-Cash | 10.4 | |||||
| Earnings Yield (Greenblatt) % | -4.67 | |||||
| FCF Yield % | -3.69 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arovella Therapeutics Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.012 | ||
| EPS (TTM) (€) | -0.006 | ||
| Beta | -0.1 | ||
| Volatility % | 54.1 | ||
| 14-Day RSI | 48.39 | ||
| 14-Day ATR (€) | 0.003872 | ||
| 20-Day SMA (€) | 0.10715 | ||
| 12-1 Month Momentum % | 105.94 | ||
| 52-Week Range (€) | 0.0485 - 0.128 | ||
| Shares Outstanding (Mil) | 1,059.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arovella Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arovella Therapeutics Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arovella Therapeutics Ltd Frequently Asked Questions
What is Arovella Therapeutics Ltd(FRA:E4NA)'s stock price today?
The current price of FRA:E4NA is €0.10. The 52 week high of FRA:E4NA is €0.13 and 52 week low is €0.05.
When is next earnings date of Arovella Therapeutics Ltd(FRA:E4NA)?
The next earnings date of Arovella Therapeutics Ltd(FRA:E4NA) is 2025-02-28 Est..
Does Arovella Therapeutics Ltd(FRA:E4NA) pay dividends? If so, how much?
Arovella Therapeutics Ltd(FRA:E4NA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers